Agenus shared a post on LinkedIn:
“At ESMOGI26, Agenus will share updated long-term follow-up from the Phase 1b study evaluating botensilimab plus balstilimab (BOT+BAL) in patients with MSS metastatic colorectal cancer without active liver metastases.
The presentation reflects an additional year of follow-up from the 123-patient cohort previously presented at ESMO GI 2025.
Watch below for presentation timing and details.”
More posts about Agenus.